Mirikizumab IV

DRUG3 trials

Conditions

Ulcerative Colitis

Phase 3

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

CompletedNCT03524092

Eli Lilly and CompanyUlcerative Colitis

Start: 2018-10-19End: 2025-02-17Updated: 2026-05-13

A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis

WithdrawnNCT04469062

Eli Lilly and CompanyUlcerative Colitis

Start: 2021-04-20End: 2024-06-05Updated: 2021-05-06

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

CompletedNCT05784246

Eli Lilly and CompanyUlcerative Colitis

Start: 2023-11-22End: 2026-05-01Updated: 2026-06-03

Journal of Crohn s and Colitis2026-01-01

P0564 Optimizing Ulcerative Colitis maintenance treatment: Indirect comparison on number needed to treat among interleukin-23p19 inhibitors highlights mirikizumab’s efficacy

Journal of Crohn s and Colitis2026-01-01

P0775 Efficacy and safety of mirikizumab as maintenance therapy in East Asian patients with moderately to severely active ulcerative colitis: subpopulation results from the phase 3 Lucent-2 study

Journal of Crohn s and Colitis2026-01-01

Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint

Journal of Crohn s and Colitis2025-07-12

Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.

2025-07-0113 citations

Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumab.

2025-07-01

Fecal Calprotectin and C-Reactive Protein Association With Histologic and Endoscopic Endpoints in Mirikizumab-Treated Patients With Ulcerative Colitis

Crohn s & Colitis 3602025-04-011 citations

Long-Term Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis: An Integrated 2-Year Safety Analysis

The American Journal of Gastroenterology2025-03-121 citations

MATCHING-ADJUSTED INDIRECT COMPARISON ON CLINICAL REMISSION FOR MIRIKIZUMAB AND RISANKIZUMAB MAINTENANCE IN THE TREATMENT OF ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS

Inflammatory Bowel Diseases2025-02-01

Efficacy and Safety of Mirikizumab in the Treatment of Moderately to Severely Active Ulcerative Colitis Regardless of Baseline Modified Mayo Score: Results From the Phase 3 LUCENT Trials

Crohn s & Colitis 3602025-01-081 citations

P1089 Efficacy and safety of mirikizumab as induction and maintenance treatment in adults 60 years or older with moderately to severely active ulcerative colitis

Journal of Crohn s and Colitis2025-01-011 citations

P0752 Efficacy and safety of the mirikizumab extended induction cohort at 152 weeks of continuous treatment for moderately to severely active Ulcerative Colitis: Results from the LUCENT-3 open-label extension study

Journal of Crohn s and Colitis2025-01-011 citations

P0666 Early symptom improvements predict later clinical response and remission at week 12 for patients with ulcerative colitis treated with mirikizumab in the LUCENT-1 study

Journal of Crohn s and Colitis2025-01-01

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

CPT Pharmacometrics & Systems Pharmacology2024-12-183 citations

Patient and Healthcare Professional Satisfaction, Acceptability, and Preference Experiences With Mirikizumab Administration for Ulcerative Colitis: An International Survey

Crohn s & Colitis 3602024-10-01

Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme

Journal of Crohn s and Colitis2024-06-1214 citations

Mirikizumab Exposure–Response Relationships in Patients with Moderately‐to‐Severely Active Ulcerative Colitis in Randomized Phase II and III Studies

Clinical Pharmacology & Therapeutics2024-05-265 citations

Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) Studies

Crohn s & Colitis 3602024-01-019 citations

OP14 Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative Colitis

Journal of Crohn s and Colitis2024-01-015 citations

P901 Extended induction response over time in patients with moderately-to-severely active Ulcerative Colitis treated with mirikizumab in the LUCENT-1 and -2 trials

Journal of Crohn s and Colitis2024-01-011 citations

26 more papers not shown

Mirikizumab IV

Sponsors

Conditions

Phase 3

Related Papers